ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary...
Transcript of ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary...
![Page 1: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/1.jpg)
ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe
Preliminary Findings
Nathan I Cherny Norman Levan Chair in Humanistic Medicine Dept Oncology Unit Head: Cancer pain and palliative Medicine Shaare Zedek Medical Center [email protected]
![Page 2: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/2.jpg)
Background
![Page 3: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/3.jpg)
Project background
ESMO is committed to assuring timely and optimal treatment of cancer patients.
The availability of opioids and anti-neoplastic medicines directly affects the daily practice of ESMO members and their ability to treat cancer patients according to the ESMO Clinical Practice Guidelines.
Affordibility of medications impacts on just distibution of care
![Page 4: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/4.jpg)
Common issues with anti-neoplastic agents
Limitations in formulary No comprehensive mapping of formularies in Europe
Actual availability Recent drug shortages
Barriers to access to expensive drugs
Resource allocation issues High out of pocket expense
![Page 5: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/5.jpg)
Study development, design, methodology
![Page 6: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/6.jpg)
Aims of the Study
To Evaluate in Europe 1. formulary availability of licensed anti-neoplastic
medicines across Europe
2. Patient out of pocket cost for the medication
3. Pre approval requirements and delays
4. The actual availability of the medication for a patient with a valid prescription
5. Factor adversely impacting availability
![Page 7: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/7.jpg)
Project leaders
Alexandru Eniu, Romania ESMO Emerging Countries Committee Chair
Nathan Cherny, Israel ESMO Palliative Care Working Group Chair
ESMO Committees involved in developing and completing the
survey ESMO Membership and National Representatives Committee ESMO Public Policy Committee ESMO Educational Committee ESMO Community Oncology Working Group
![Page 8: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/8.jpg)
Coordinating and Collaborating Partners
Coordinating Organization ESMO
Collaborating Project Partners 1. World Health Organization (WHO) 2. Union for International Cancer Control (UICC) 3. Institute of Cancer Policy, Kings College, London 4. European Medicines Agency (EMA) 5. European Society of Oncology Pharmacy (ESOP)
![Page 9: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/9.jpg)
Survey development
Modelled on previous opioid studies
Highlights common oncologic conditions
2 parts 1. General questions about health care system 2. Formulary assessment for 13 diseases
![Page 10: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/10.jpg)
Diseases surveyed
Breast Cancer Lung Cancer Colorectal Cancer Prostate Cancer Ovarian Cancer Sarcoma
Pancreatic cancer Germ cell Tumors Renal cell Cancer GIST Urothelial Cancers Gastric and esophageal cancer Melanoma
![Page 11: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/11.jpg)
General Questions regarding health care system
![Page 12: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/12.jpg)
Example of form :Metastatic Breast Cancer
![Page 13: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/13.jpg)
Identification of data reporters
National representatives
Known credible professionals nominated by coordinating and collaborating partners
Minimum of 2 reporters for each country nominated
Total 185 from 49 countries
![Page 14: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/14.jpg)
Data Collection and Management
Electronic dissemination of surveys and automated data entry Crosschecking data entry and clarification of discrepancies
between reporters Conflicting data (Individual reporters, multiple reporters) Priority given to highly credentialed reporters Representative data presented
Open peer review of preliminary representative data
(planned)
![Page 15: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/15.jpg)
Color coded tabulated data presentation
Color coded tabulated data presentation Methodology developed on ESMO Opioid studies Established and widely endorsed clarity Readily allow cross county comparisons Facilitates presentation of changes over time
![Page 16: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/16.jpg)
Expected results and outcomes: General
Identification of inequalities in availability and patient costs Potential Users
1. European Medicines Agency (EMA) 2. European Union (EU) 3. WHO 4. Ministries of Health in improving national cancer control plans. 5. National cancer organizations 6. Patient advocacy organizations
Future Uses Cross correlation with essential drug lists Evaluation of formulary priorities
![Page 17: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/17.jpg)
Results
![Page 18: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/18.jpg)
Results
102/185 responses from 46/49 countries Respondents 25 oncology pharmacists (22 countries) 77 oncologists 74 Academic cancer centers or hospitals
![Page 19: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/19.jpg)
Diseases with high levels of variability in cost and availability
Renal cell Melanoma
![Page 20: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/20.jpg)
Renal Cell: Formulary and cost
![Page 21: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/21.jpg)
![Page 22: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/22.jpg)
![Page 23: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/23.jpg)
Renal Cell : Actual Availability
![Page 24: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/24.jpg)
Colorectal
![Page 25: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/25.jpg)
Colorectal
![Page 26: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/26.jpg)
Renal Cell : Preapproval requirements and delays >4 weeks
![Page 27: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/27.jpg)
![Page 28: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/28.jpg)
![Page 29: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/29.jpg)
Melanoma: Formulary and cost
![Page 30: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/30.jpg)
![Page 31: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/31.jpg)
![Page 32: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/32.jpg)
Melanoma : Actual Availability
![Page 33: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/33.jpg)
Colorectal
![Page 34: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/34.jpg)
Colorectal
![Page 35: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/35.jpg)
Melanoma : Preapproval requirements and delays >4 weeks
![Page 36: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/36.jpg)
![Page 37: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/37.jpg)
![Page 38: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/38.jpg)
Diseases with segmental of variability in cost and availability
Sarcoma Lung Cancer
Breast Cancer Colorectal Cancer
Ovarian Cancer
![Page 39: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/39.jpg)
Lung Cancer: Formulary and cost
![Page 40: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/40.jpg)
![Page 41: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/41.jpg)
![Page 42: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/42.jpg)
![Page 43: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/43.jpg)
![Page 44: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/44.jpg)
Lung: Actual Availability
![Page 45: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/45.jpg)
![Page 46: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/46.jpg)
![Page 47: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/47.jpg)
![Page 48: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/48.jpg)
![Page 49: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/49.jpg)
Colorectal: Formulary and cost
![Page 50: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/50.jpg)
![Page 51: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/51.jpg)
![Page 52: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/52.jpg)
Colorectal : Actual Availability
![Page 53: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/53.jpg)
Colorectal
![Page 54: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/54.jpg)
![Page 55: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/55.jpg)
Colorectal : Preapproval requirements and delays >4 weeks
![Page 56: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/56.jpg)
![Page 57: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/57.jpg)
![Page 58: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/58.jpg)
Diseases with less variability
Adjuvant Breast Cancer Gastric
Germ Cell Urothelial
![Page 59: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/59.jpg)
Germ Cell: Formulary and cost
![Page 60: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/60.jpg)
![Page 61: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/61.jpg)
![Page 62: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/62.jpg)
Germ Cell : Actual Availability
![Page 63: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/63.jpg)
Colorectal
![Page 64: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/64.jpg)
Colorectal
![Page 65: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/65.jpg)
Urothelial : Formulary and cost
![Page 66: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/66.jpg)
![Page 67: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/67.jpg)
![Page 68: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/68.jpg)
Urothelial : Actual Availability
![Page 69: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/69.jpg)
Colorectal
![Page 70: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/70.jpg)
Colorectal
![Page 71: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/71.jpg)
Preliminary Conclusions
There are substantial differences in formulary availability , out of pocket costs and actual availability for many medications
These differences
Are more profound in Eastern European Countries Are related to the cost of new agents
The impact of these differences are most profound in diseases where outcomes are dependent on availability of expensive anticancer agents such as EFGR or ALK mutated non small cell lung cancer Melanoma Renal Cell Cancer RAS/RAF wild type colorectal cancer
12/11/2015 71
![Page 72: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/72.jpg)
Preliminary Conclusions 2
These discrepancies are less pronounced in curative settings This is best illustrated for Trastuzumab in adjuvant breast cancer which
though expensive is generally subsidized and available in most countries The discrepancies are even less when curative treatment do not require
expensive therapies such as in Germ Cell Tumors
Requirement for pre approval of treatments for purposes of coverage or reimbursement is more common in Israel and many Eastern European Countries is common for expensive anti cancer therapies does not usually delay treatment by more than 4 weeks
Delays of more than 4 weeks caused by the pre-approval process tended to occur in specific countries in Eastern Europe (Albania, Armenia, Georgia, Romania)
12/11/2015 72
![Page 73: ESMO Study of formulary listing, out of pocket cost and ...€¦ · ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe](https://reader034.fdocuments.net/reader034/viewer/2022042612/5f60142eff3e0126327f819f/html5/thumbnails/73.jpg)
Special Acknowledgments
Coordinating Partners 1. European Society for Medical Oncology (ESMO) 2. World Health Organization (WHO 3. Union for International Cancer Control (UICC) 4. Institute of Cancer Policy, Kings College, 5. European Medicines Agency (EMA) 6. European Society of Oncology Pharmacy (ESOP)
102 individual reporters
ESMO committees 1. ESMO Presidency and executive 2. ESMO Membership and National Representatives Committee 3. ESMO Public Policy Committee 4. ESMO Educational Committee 5. ESMO Community Oncology Working Group 6. ESMO Palliative Care Working Group
Logistics Gracemarie Bricalli Tanya Kenny Marina Cogo